Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Gregory R. FribergEVP, Chief R&D Officer | Biomarin PharmaceuticalBMRN | Open-market sale | 05/07 | 05/11 | 3,281 sh | $53.85 | $176,681.85 | −6.0% |
Guyer Charles GregEVP, Chief Technical Officer | Biomarin PharmaceuticalBMRN | Open-market sale | 03/11 | 03/12 | 16,486 sh | $60.46 | $996,743.56 | −17.1% |
George Eric DavisEVP, Chief Legal Officer | Biomarin PharmaceuticalBMRN | Open-market sale | 02/26 | 02/26 | 26,061 sh | $61.36 | $1,599,102.96 | −26.5% |
Gregory R. FribergEVP, Chief R&D Officer | Biomarin PharmaceuticalBMRN | Open-market sale | 02/26 | 02/26 | 6,326 sh | $60.38 | $381,963.88 | −14.4% |
Erin BurkhartGVP, Chief Accounting Officer | Biomarin PharmaceuticalBMRN | Open-market sale10b5-1 plan | 25/05/20 | 25/05/20 | 1,786 sh | $59.31 | $105,927.66 | −11.2% |
Cristin HubbardEVP, Chief Commercial Officer | Biomarin PharmaceuticalBMRN | Open-market sale10b5-1 plan | 25/05/02 | 25/05/06 | 273 sh | $64.92 | $17,723.16 | −0.8% |
Erin BurkhartGVP, Chief Accounting Officer | Biomarin PharmaceuticalBMRN | Open-market sale10b5-1 plan | 25/03/19 | 25/03/20 | 1,295 sh | $71.52 | $92,618.4 | −7.1% |
Guyer Charles GregEVP, Chief Technical Officer | Biomarin PharmaceuticalBMRN | Open-market sale | 25/03/06 | 25/03/07 | 7,034 sh | $71.28 | $501,383.52 | −7.4% |
Erin BurkhartGVP, Chief Accounting Officer | Biomarin PharmaceuticalBMRN | Open-market sale10b5-1 plan | 25/02/24 | 25/02/25 | 1,344 sh | $68.38 | $91,902.72 | −9.3% |
Guyer Charles GregEVP, Chief Technical Officer | Biomarin PharmaceuticalBMRN | Open-market sale | 24/11/12 | 24/11/14 | 5,278 sh | $66.37 | $350,300.86 | −7.1% |
Erin BurkhartGVP, Chief Accounting Officer | Biomarin PharmaceuticalBMRN | Open-market sale10b5-1 plan | 24/08/13 | 24/08/15 | 714 sh | $90.00 | $64,260 | −4.7% |
Brian MuellerEVP, CFO | Biomarin PharmaceuticalBMRN | Open-market sale10b5-1 plan | 24/05/30 | 24/05/31 | 5,000 sh | $75.19 | $375,950 | −6.5% |
Biomarin PharmaceuticalBMRN | Open-market sale10b5-1 plan | 24/05/28 | 24/05/30 | 40,850 sh2 trades | $74.52avg. | $3,043,997.57 | −42.1% | |
Biomarin PharmaceuticalBMRN | Open-market sale10b5-1 plan | 24/05/09–24/05/10 | 24/05/13 | 40,000 sh2 trades | $81.38avg. | $3,255,200 | −7.8% | |
George Eric DavisEVP, Chief Legal Officer | Biomarin PharmaceuticalBMRN | Open-market sale10b5-1 plan | 24/05/02 | 24/05/06 | 1,850 sh | $85.01 | $157,268.5 | −3.2% |
Jeffrey Robert AjerEVP, Chief Commercial Officer | Biomarin PharmaceuticalBMRN | Open-market sale10b5-1 plan | 24/05/02 | 24/05/06 | 5,000 sh | $82.91 | $414,550 | −7.0% |
Biomarin PharmaceuticalBMRN | Open-market sale10b5-1 plan | 24/04/11–24/04/12 | 24/04/15 | 40,000 sh2 trades | $91.13avg. | $3,645,000 | −7.8% | |
Erin BurkhartGVP, Chief Accounting Officer | Biomarin PharmaceuticalBMRN | Open-market sale10b5-1 plan | 24/04/10 | 24/04/12 | 2,286 sh | $90.00 | $205,740 | −12.4% |
George Eric DavisEVP, Chief Legal Officer | Biomarin PharmaceuticalBMRN | Open-market sale10b5-1 plan | 24/03/28 | 24/04/01 | 24,602 sh | $88.34 | $2,173,340.68 | −30.6% |
Biomarin PharmaceuticalBMRN | Open-market sale | 24/03/05–24/03/06 | 24/03/07 | 2,000 sh2 trades | $86.11avg. | $172,220 | −0.4% |